Investors
Fact Sheet
Pioneering the next generation of immunotherapies
Advaxis is a development-stage biotechnology company utilizing multiple mechanisms of immunity to develop more effective and safe cancer vaccines. Using a patented system to engineer a live attenuated Listeria monocytogenes bacteria to produce a tumor-specific antigen, Advaxis' technology forces the body's immune system to process and recognize the antigen as if it were foreign, thereby creating the necessary immune response to attack the cancer.
View PDF